<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.25651.010</object-id><label>Table 1.</label><caption><p>pK<sub>a</sub>s and K<sub>i</sub>s for the studied weak base &#945;4&#946;2R ligands</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.25651.010">http://dx.doi.org/10.7554/eLife.25651.010</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"><bold>Weak base</bold></th><th valign="top"><bold>pK<sub>a</sub></bold> <break/><bold>(Basic)</bold></th><th valign="top"><bold>K<sub>i</sub></bold></th><th valign="top"><bold>Trapping</bold></th></tr></thead><tbody><tr><td valign="top"><bold>Varenicline</bold> <break/>(partial agonist)</td><td valign="top">9.2&#160;(<xref ref-type="bibr" rid="bib56">Unal et al., 2012</xref>)</td><td valign="top">0.4 nM (<xref ref-type="bibr" rid="bib45">Rollema et al., 2010</xref>)</td><td valign="top">Yes</td></tr><tr><td valign="top"><bold>Lobeline</bold> <break/>(partial agonist)</td><td valign="top">8.8 (<xref ref-type="bibr" rid="bib17">Drugbank, 2016</xref>)</td><td valign="top">four nM (<xref ref-type="bibr" rid="bib14">Damaj et al., 1997</xref>)</td><td valign="top">Yes</td></tr><tr><td valign="top"><bold>Epibatidine</bold> <break/>(agonist)</td><td valign="top">9.5 (<xref ref-type="bibr" rid="bib12">ChEMBL, 2017</xref>)</td><td valign="top">0.01&#8211;0.05 nM (<xref ref-type="bibr" rid="bib59">Whiteaker et al., 1998</xref>; <xref ref-type="bibr" rid="bib3">Badio et al., 1994</xref>)</td><td valign="top">Yes</td></tr><tr><td valign="top"><bold>Nicotine</bold> <break/>(agonist)</td><td valign="top">8.0 (<xref ref-type="bibr" rid="bib4">Barlow and Hamilton, 1962</xref>)</td><td valign="top">eight nM (<xref ref-type="bibr" rid="bib59">Whiteaker et al., 1998</xref>)</td><td valign="top">No</td></tr><tr><td valign="top"><bold>DH&#946;E</bold> <break/>(competitive antagonist)</td><td valign="top">7.3 (<xref ref-type="bibr" rid="bib11">ChEMBL, 2017</xref>)</td><td valign="top">0.3 &#956;M (<xref ref-type="bibr" rid="bib59">Whiteaker et al., 1998</xref>)</td><td valign="top">No</td></tr><tr><td valign="top"><bold>Mecamylamine</bold> (noncompetitive antagonist)</td><td valign="top">11.2 (<xref ref-type="bibr" rid="bib42">Remington and Beringer, 2006</xref>; <xref ref-type="bibr" rid="bib35">Nangia et al., 1996</xref>)</td><td valign="top">&gt;1 mM (<xref ref-type="bibr" rid="bib59">Whiteaker et al., 1998</xref>)</td><td valign="top">No</td></tr></tbody></table></table-wrap>